But this comes in second-line breast cancer, a use the group isn’t pursuing.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.